今天，CXO龙头药明康德发布重磅业绩预告： 公司预计2025年实现营收约454.56亿元，同比增长15.84%，归母净利润约191.51亿元，同比增长约 102.65%。 现在是业绩季，多少市场资金在盯着每日更新的业绩榜单，药明康德的业绩暴增，自然引发了市场对 CRO板块的狂欢。 当然，光靠药明康德的一己之力，也还带不动整个医药股赛道的持续性行情。 更重要的是，近期大热的AI应用行情开始向AI医疗方向演进。 相关消息： 1，OpenAI周一在社交媒体X平台上宣布，已收购医疗科技初创公司Torch。 OpenAI近期还发布了多款面向医疗机构的企业级产品，首批合作伙伴包括HCA Healthcare等大型医疗系 统——这些动向标志着OpenAI不断加码"AI+医疗"业务的雄心。 2，英伟达与美国制药巨头礼来周一宣布，双方将在未来五年内投入10亿美元，在旧金山湾区建设一座 联合研究实验室，旨在加速人工智能在制药行业中的应用。 礼来是越来越多依赖先进AI模型的制药公司之一，这些模型被用于新药的设计与发现，目标是大幅缩 短新药从研发到上市所需的时间。 OpenAI和英伟达两大美国龙头都在加码AI医疗，风向趋势再清楚不过 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

1月13日，百川智能创始人兼CEO王小川公开表示，公司将于2027年启动IPO上市。 10月，百川智能发布首个循证增强医疗大模型Baichuan-M2Plus，幻觉率较通用大模型显著降低，相比 Deepseek降低3倍，可信度比肩资深临床医生水准。 公开信息显示，百川智能于2024年完成50亿元A轮融资，估值超过130亿元。 就在近日，智谱、MiniMax相继在港股上市，成为某种意义上的"上岸"。 对此，王小川评价道："他们主要还是踩在通用模型技术红利和政策支持的基础上，但目前他们的市值 和商业化能力并不匹配。" 去年底，百川智能发布PAPA（PlayBook Animated Proactive Agent），这款主动陪伴患者的医疗Agent平 台，能够以月甚至年为单位，从提醒用药到动态调整健康计划，主动追踪并管理患者的康复进程。 百川智能成立于2023年，与智谱、MiniMax、月之暗面、阶跃星辰、零一万物并称"国产大模型六小 龙"。 "AI医疗今天也是大模型竞争中的一个范式，与虽然它的成熟会晚一点，在后面我们的路径，肯定也是 奔着上市去的"，王小川表示。 在"六小龙"中，百川智能是第一个All in 垂 ...

Core Viewpoint - The strategic partnership between Eli Lilly, a leading pharmaceutical company, and Nvidia, a top technology giant, marks a significant shift in the pharmaceutical industry, focusing on AI-driven drug development and manufacturing processes [1][14]. Group 1: Partnership Details - Eli Lilly and Nvidia will invest $1 billion over five years to establish a joint innovation lab in the San Francisco Bay Area [1]. - The lab will not only serve as a computing center but will also aim to completely restructure the drug development process using AI [2]. - The partnership will utilize Nvidia's latest AI chip architecture, Vera Rubin, which is designed for high-precision scientific calculations essential for drug development [2][3]. Group 2: Technological Integration - The collaboration will integrate hardware and software, with Nvidia's BioNeMo platform and Eli Lilly's TuneLab platform combining to enhance drug discovery [3][4]. - BioNeMo will function as a generative AI platform for biology, capable of generating new protein structures, while Eli Lilly will contribute its extensive historical experimental data [3][4]. - The partnership aims to address the data and model gap in AI healthcare, leveraging federated learning technology [4]. Group 3: Manufacturing Innovations - The collaboration extends to manufacturing, with plans to create a "digital twin" of Eli Lilly's production line using Nvidia's Omniverse platform [5]. - This digital twin will simulate production processes to optimize supply chain efficiency, potentially leading to significant revenue increases for high-demand products [5]. Group 4: Industry Context and Implications - Eli Lilly's decision to partner with Nvidia reflects a strategic move to overcome the challenges of traditional drug development, which is often time-consuming and costly [6][7]. - The partnership signifies a shift from a "Discovery" to a "Design" paradigm in drug development, allowing for targeted molecular design rather than random screening [7][8]. - The collaboration is expected to accelerate industry changes, prompting other major pharmaceutical companies to seek similar technological partnerships [16][18]. Group 5: Future Outlook - The partnership is seen as a potential turning point in AI-driven pharmaceutical development, creating a new model of collaboration between top pharmaceutical and technology companies [15][16]. - The competition in the pharmaceutical industry is likely to intensify as companies race to secure technological alliances, with AI becoming a critical component of drug development [19][20].

多只基金宣布限购 业内人士：主要是为了控制基金规模 1月13日，永赢基金官宣，决定自1月14日起，对旗下两只热门产品——永赢高端装备智选与永赢信息产 业智选实施申购限额。伴随近日火爆行情，中欧、平安、华泰柏瑞、兴全、摩根等多家基金公司旗下产 品也纷纷宣布限购，其中不乏绩优基金。业内人士表示，部分绩优基金"闭门谢客"，这与开年以来A股 市场表现较为突出有关，绩优基金的限购反映出基金管理人的谨慎态度。基金经理和基金公司将更加理 性地看待产品业绩的短期爆发，更加关注产品净值的稳定增长，更加关心持有人的持续盈利。（中国基 金报） 汇丰银行称金价或在上半年触及5000美元关口 今年以来，国际金价已经上涨约6%。汇丰银行分析认为，当前金价上涨动能依旧存在，金价可能在 2026年上半年触及每盎司5000美元关口。该行指出，避险需求、美元走弱及政策不确定性共同支撑金 价，而多国财政赤字扩大也持续刺激黄金配置需求。与此同时，由于白银市场供应持续紧张，国际银价 呈现显著补涨特征。伦敦现货市场白银价格今年以来涨幅已超17%，显著跑赢金价。市场分析称，当前 白银供应短缺很难在短期内得到缓解。在这种环境下，市场预期白银价格将继续保持上 ...

Market Overview - The A-share market experienced a pullback on January 13, with the Shanghai Composite Index dropping nearly 1% and the ChiNext Index falling over 2% [1][14] - The total trading volume across all A-shares reached approximately 3.7 trillion yuan, setting a new historical record and surpassing 3 trillion yuan for three consecutive trading days [1][14] - The Shanghai Composite Index closed down 0.64% at 4138.76 points, while the Shenzhen Component Index fell 1.37% and the ChiNext Index decreased by 1.96% [1][14] Sector Performance - The commercial aerospace sector saw a significant decline, with stocks like Aerospace Huanyu dropping over 18% and Shaoyang Hydraulic falling more than 13% [8][22] - The semiconductor sector also faced losses, with companies like Changguang Huaxin and Saiwei Microelectronics dropping over 10% [15] - Conversely, the insurance and banking sectors performed well, with Xinhua Insurance rising over 4% to reach a new historical high and China Life increasing by more than 3% [15] AI Medical Sector - The AI medical concept saw strong performance, with stocks such as Nossger and Hongbo Pharmaceutical hitting the daily limit, and Di'an Diagnostics rising nearly 12% [2][16] - OpenAI's recent launch of ChatGPT Health aims to integrate multi-source health data, marking a significant advancement in AI's penetration into the healthcare sector [18] - The domestic AI medical application is accelerating, with Ant Group's AI medical product achieving over 15 million monthly active users, indicating a deepening integration of internet healthcare and AI [18] Innovative Drug Sector - The innovative drug concept also gained traction, with stocks like Rongchang Bio and Puris reaching the daily limit of 20% [5][19] - The National Medical Products Administration (NMPA) plans to implement precise policies to support innovative drugs, including establishing a market exclusivity system for pediatric and rare disease medications by 2026 [19] - Several new drugs have been approved for market release in early 2026, indicating a recovery trend in the biopharmaceutical sector [19] GEO Concept - The GEO (Generative Engine Optimization) concept became active, with Tianlong Group hitting the daily limit and stocks like Zhidema and Yidian Tianxia rising over 10% [20][21] - The GEO business of Yingu Media is still in the planning stage and has not yet formed a mature business model, indicating uncertainty in market recognition and profitability [21] Commercial Aerospace Sector Risks - The commercial aerospace sector is facing significant volatility, with companies like Aerospace Huanyu and Shaoyang Hydraulic issuing warnings about high speculative risks due to their stock prices deviating significantly from market trends [10][24] - Companies in this sector have reported that their products are primarily used in industries like metallurgy and hydropower, rather than directly serving the commercial aerospace sector [24][25]

| | 特定对象调研 分析师会议 √ □ | | --- | --- | | 投资者关系 | 媒体采访 业绩说明会 □ □ | | | 新闻发布会 路演活动 □ □ | | 活动类别 | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位 | 国信证券组织的投资者 | | 时间 | 2026 年 1 月 11 日 | | 地点 | 进门财经电话会议 | | 上市公司接 | 副总裁、首席信息官 吴维严 | | | 副总裁、董事会秘书 陶钧 | | 待人员姓名 | 医策科技 王晓梅 CEO | | | 公司管理层对投资者提问的回复情况如下： | | | 1．AI 对医疗行业是否带来结构性重塑？ | | | 答：将推动医疗健康应用快速发展，尤其在基层医疗与健康 | | | 管理场景。但复杂病症与循证医学领域的 AI 应用仍需高质量多 | | | 模态数据支撑。患者端将受益于全生命周期健康管理；在医生端， | | | AI 主要作为辅助工具，助力经验知识平民化。迪安通过"临床科 | | 投资者关系 | 研+基层赋能"闭环推动产品落地。 | | 活动主要内 | 【风险提示：目前公司的 AI ...

A股今日（1月13日）全线回调，沪指午后跌近1%，创业板指一度跌超2%，全A成交近3.7万亿元，再度刷 新历史纪录，且已连续三个交易日突破3万亿元。港股方面，恒生指数强势上扬涨近1%，恒生科技指数盘 中一度翻绿，尾盘翻红。 具体来看，沪指早盘窄幅震荡，尾盘加速跳水，创业板指、科创50指数大幅下探。截至收盘，沪指跌0.64%报 4138.76点，深证成指跌1.37%，创业板指跌1.96%，科创50指数跌2.8%，沪深北三市合计成交约3.7万亿元，较 此前一日增加约540亿元。 全A超3700股飘绿，近期强势的商业航天概念大幅回调，此前4个交易日翻倍的邵阳液压大跌超13%，中国卫 通、航天发展、江顺科技等均跌停；半导体板块亦下挫，长光华芯、赛微微电等跌超10%；保险、银行板块逆 市拉升，新华保险涨超4%续创历史新高，中国人寿涨逾3%；AI医疗概念活跃，诺思格、泓博医药等涨停；创 新药概念拉升，荣昌生物、普蕊斯等涨停。值得注意的是，大牛股锋龙股份已连续斩获13个涨停板，鲁信创 投13日收获11板，引力传媒（603598）7日斩获6板。 医药股拉升 AI医疗概念盘中强势拉升，截至收盘，诺思格、泓博医药、博济医药等涨停 ...

Market Overview - A-shares opened high but closed lower, with the Shanghai Composite Index down 0.64%, Shenzhen Component Index down 1.37%, and ChiNext Index down 1.96%. The total trading volume in the Shanghai and Shenzhen markets was approximately 3.70 trillion yuan, showing a slight increase compared to the previous trading day. More than 3,700 stocks declined [1] Industry Insights - The commercial aerospace sector saw significant activity, leading to a market pullback. However, this correction is considered normal after continuous gains, and the spring market trend is expected to continue. Investors are advised to focus on technology growth and related sectors such as commercial aerospace, AI applications, and new energy, while also considering cash flow/dividend assets to mitigate market volatility [1] - The medical services, precious metals, and GEO concept stocks were among the top gainers today, while commercial aerospace, semiconductors, and chemical fiber industries experienced the largest declines [1] Pharmaceutical Sector Highlights - The pharmaceutical sector led the market gains due to several key developments: 1. Rongchang Bio signed an exclusive licensing agreement with AbbVie for RC148, with a total transaction value of 5.6 billion USD, highlighting the significant market potential of the PD-1/VEGF dual antibody track [2] 2. WuXi AppTec, a leading CXO, announced its 2025 performance forecast, expecting annual revenue of 45.456 billion yuan, a year-on-year increase of 15.84%, exceeding expectations [2] 3. Tempus AI reported better-than-expected earnings, with diagnostic business revenue of 955 million USD, a year-on-year growth of 111%, indicating ongoing global advancements in AI medical technology [2] - The pharmaceutical sector's global competitiveness continues to strengthen, with ongoing international expansion and commercial profitability [2] Power Grid Sector Developments - The domestic power grid performed relatively well in the afternoon, driven by the demand for renewable energy consumption from large-scale wind and solar projects. The vast territory of China necessitates long-distance transportation, which is expected to further stimulate demand for UHV (Ultra High Voltage) construction. During the 14th Five-Year Plan period, UHV DC is expected to maintain an annual approval pace of 3 to 4 lines, while UHV AC is anticipated to approve an average of 2 large projects annually [2] - In North America, explosive growth in AIDC (Artificial Intelligence Data Center) is creating new electricity demand, and China's complete power grid industry chain, efficient delivery, and rich overseas experience position it as a key supplier to fill this gap [2]

主线热点 2026年1月12日凌晨，谷歌宣布与沃尔玛、塔吉特、Wayfair、Etsy等全球头部零售商达成合作，并正式 开源面向电商领域的AI智能体协议通用商业协议。隔夜美股中概股集体走强，阿里巴巴大涨10%。此前 受到马斯克宣布在7天内开源X最新一代推荐算法提振的AI应用端延续强势，GEO概念天龙集团、引力 传媒、利欧股份、三维通信实现连板晋级，不过20厘米中军蓝色光标放量巨震，仍受到其进入重点监控 名单影响，拖累弹性方向人气股流金科技、易点天下、值得买等纷纷炸板回落。整个应用端连板高度和 连板股家数的显著减少，对于弹性方向的赚钱效应压制明显。不过随着今日分歧的率先释放，若市场短 线情绪能够企稳，不排除20厘米方向部分个股存在反包修复可能。 英伟达宣布，将在未来五年内与礼来共同投资10亿美元建立人工智能药物实验室。AI医疗、AI制药概 念受此消息刺激双双爆发，泓博医药、美年健康一字涨停，带动思创医惠、诺思格、博济医药、贝瑞基 因等多股涨停。综合多券商研报观点，AI制药核心价值在于大幅提升药物早研效率，候选药物从靶点 发现到临床前候选药物确认时间有望显著缩短三分之二以上，因此一些主营聚焦于临床前试验的CXO ...